New domestic bivalent cervical cancer vaccine is listed in Guangdong

　　In China, cervical cancer ranks first in the incidence and mortality of malignant tumors in female reproductive system. In response to the World Health Organization’s plan to eliminate cervical cancer, Guangdong Preventive Medicine Association held a seminar on prevention and control strategies of cervical cancer on August 6, and experts discussed topics such as prevention and control strategies, screening ideas and vaccination. On the same day, the new domestic bivalent cervical cancer vaccine was launched in Guangdong, and women aged 9-30 can make an appointment for vaccination.

　　Yu Wenzhou, chief physician of China Center for Disease Control and Prevention, said that cervical cancer is the only malignant tumor with definite cause among all human cancers at present, and it is also the first malignant tumor that is expected to be eliminated by HPV vaccination. However, according to the conference, the vaccination rate of HPV vaccine in China is still low, and the vaccination rate of children aged 9-14 is even less than 1%.

　　Wu Shengming, president of Guangdong Preventive Medicine Association, appealed that HPV vaccination is the most effective and economical means to prevent cervical cancer. The whole society should pay more attention to the early prevention and treatment of cervical cancer. The earlier the vaccination, the better the vaccine effect. It is suggested that girls who have not had sex at the age of 9-14 should be the primary vaccination target.

　　The incidence of cervical cancer is younger.

　　Experts call for vaccination and screening.

　　Zheng Huizhen, chief expert of disease control of Guangdong Preventive Medicine Association, said that in 2020, there will be about 110,000 new cases of female cervical cancer in China and nearly 60,000 deaths. The epidemiological study of female cervical cancer in China shows that there are two peaks of high-risk HPV infection, the first peak is 15-24 years old, and the second peak is 40-44 years old.

　　"More than 99% of cervical cancers are caused by persistent infection with high-risk HPV virus." Wang Ming, a professor at Guangzhou Preventive Medicine Association, said. This also means that if you can vaccinate early before the peak of infection, you can greatly reduce the risk of HPV infection and cervical cancer.

　　"With the change of lifestyle, the age of the first sexual behavior of teenagers in China is constantly moving forward. In recent years, the incidence of cervical cancer in China has also shown a younger and upward trend. " Lu Jianyun, director of Guangzhou Baiyun District Center for Disease Control and Prevention, said, "Therefore, it is necessary to vaccinate as soon as possible, especially before girls have sex for the first time and have not been infected with HPV."

　　In fact, there is a mature model for the prevention and treatment of cervical cancer in China. Qian Deying, chief physician of the Department of Obstetrics and Gynecology, Guangdong Provincial People’s Hospital, said that the infection rate of HPV virus in women is very high, but most of them can be eliminated through the body’s own immune mechanism, and it usually takes more than ten years for persistent HPV virus infection to develop into cervical cancer. "It is precisely because of this process that we can carry out a lot of prevention work. Cancer can be controlled from the source by vaccination and regular screening. "

　　She said that the prevention and treatment of cervical cancer should follow the three-level prevention and treatment ideas. The first-level prevention is to vaccinate HPV to prevent HPV infection; Secondary prevention is preclinical prevention, and cervical screening is carried out regularly. Women who have been vaccinated with bivalent and tetravalent vaccines are advised to start screening at the age of 25-30, with a frequency of 5 years, and those who have been vaccinated with nine-valent vaccines should start screening at the age of 30-35, once every 10 years; Tertiary prevention is the clinical treatment of precancerous lesions and early cancer.

　　"You don’t have to worry too much. Early cervical cancer can be cured by surgery." Qian Deying emphasized that if screening is done well, cervical cancer can be "suppressed" from the symptoms.

　　New vaccine goes on the market in Guangdong

　　You can make an appointment for vaccination in community hospitals.

　　On August 6th, the new domestic bivalent cervical cancer vaccine "Wozehui" was listed in Guangdong. The vaccine is suitable for women aged 9-30. At present, most community clinics in Guangdong Province have completed the supply.

　　It is understood that this new vaccine has passed the clinical trial of bivalent HPV vaccine with the largest sample size in China, which confirmed its vaccination safety and effectiveness. At present, five HPV vaccine products have been registered in China, including three imported HPV vaccines and two domestic HPV vaccines. Wang Ming said that bivalent, tetravalent and nonavalent HPV vaccines are basically the same in terms of effectiveness and safety in preventing HPV16/18 type-related cervical cancer, and different vaccines correspond to different vaccination ages. The listing of this new vaccine will effectively alleviate the shortage of HPV vaccine in short supply.

　　According to the latest policy of our province, from September 2022, girls under the age of 14 who have a student status in Guangdong Province and have entered the first grade of junior high school and have not been vaccinated with HPV vaccine can be vaccinated with domestic bivalent HPV vaccine for free. Zheng Huizhen said that in addition to the free vaccination population, people who voluntarily vaccinate at their own expense can make an appointment for vaccination clinics on the website of the Guangdong Provincial Center for Disease Control and Prevention or make an appointment at a community hospital.

　　In terms of cost, the price of the new vaccine in Guangdong is 339 yuan, plus the vaccination service fee in 21 yuan, the final vaccination price is 360 yuan. In terms of vaccination procedures, women aged 9-30 can receive three doses in October, February and June, and girls aged 9-14 can also receive two doses in October and June. At present, most communities with vaccination qualifications can be vaccinated with this vaccine.